RecruitingNCT06105411

Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions


Sponsor

Peter MacCallum Cancer Centre, Australia

Enrollment

10 participants

Start Date

Dec 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.


Eligibility

Min Age: 18 Years

Inclusion Criteria5

  • Patient has provided written informed consent
  • Aged 18 years or older at written informed consent
  • Within 2 weeks of proven or probable or possible invasive fungal infection (IFI) diagnosis as per EORTC criteria
  • Imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET/CT with lesions at least 8mm in diameter
  • Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits such as follow up

Exclusion Criteria2

  • Women who are pregnant or lactating.
  • Iron infusion within one week prior to scan

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TEST68Ga-labelled TAFC PET/CT scan

68Ga-labelled TAFC PET/CT scan (whole body)


Locations(1)

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06105411


Related Trials